Access Delayed, Access Denied: Waiting for New Medicines in Canada 2008

Printer-friendly version

This is the Fraser Institute's second annual report on the amount of time patients must wait to access new medicines in Canada. The purpose of this report is: (1) to draw attention to the impact that Canadian public policies and institutions have on lengthening the time it takes for patients to access newly invented, patented prescription drugs; (2) to compare consumer access to new drugs under government drug insurance programs with access under private sector drug insurance in Canada; and (3) to offer alternative policy options that could improve access to new drugs in Canada.

More from this study